Rapid Revenue ScalingSustained, large percentage revenue growth demonstrates successful commercial adoption and market demand for products. Over a 2-6 month horizon, this supports continued top-line momentum, expands customer proof points, and increases optionality for partnerships or non-dilutive financing as product traction solidifies.

Strong Gross MarginsA ~52% gross margin indicates the business can convert revenue into contribution at a healthy rate versus peers. Durable margin structure supports scalability: as fixed selling and R&D leverage improves, higher margins can materially reduce the cash required to reach breakeven and improve long-term unit economics.

Debt-free, Equity-funded Balance SheetZero debt and ~¥5.5b equity provide durable financial flexibility, lowering refinancing risk and enabling strategic choices (R&D investment, partnerships, or staged commercialization). For 2-6 months this reduces solvency risk and preserves capacity to raise capital on favorable terms if needed.

Bears Say

High Operating Cash BurnConsistently negative operating and free cash flow at scale indicates the business is consuming cash faster than it generates it. Over months this creates runway pressure, raises likelihood of capital raises (dilution risk), and constrains ability to invest countercyclically or sustain long development timetables without new financing.

Large Operating And Net LossesDeep, persistent operating and net losses show the company has not yet achieved operating leverage. This erodes equity and requires ongoing funding. Structural profitability risk means management must materially cut costs or grow revenue substantially to reach breakeven, a multi-quarter challenge that affects long-term viability.

Negative Return On Equity / Capital EfficiencyA negative ROE (~-11.7%) signals poor capital efficiency and that invested equity is being eroded, not grown. Persisting negative returns reduce investor appetite for follow-on funding, raise cost of capital, and imply structural issues in converting R&D and sales investment into profitable growth over the medium term.

4894 FAQ

What was Cuorips Inc.’s price range in the past 12 months?

Cuorips Inc. lowest stock price was ¥5120.00 and its highest was ¥12300.00 in the past 12 months.

What is Cuorips Inc.’s market cap?

Cuorips Inc.’s market cap is ¥92.97B.

When is Cuorips Inc.’s upcoming earnings report date?

Cuorips Inc.’s upcoming earnings report date is May 20, 2026 which is in 89 days.

How were Cuorips Inc.’s earnings last quarter?

Cuorips Inc. released its earnings results on Feb 18, 2026. The company reported -¥30.15 earnings per share for the quarter, missing the consensus estimate of N/A by -¥30.15.

Is Cuorips Inc. overvalued?

According to Wall Street analysts Cuorips Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cuorips Inc. pay dividends?

Cuorips Inc. does not currently pay dividends.

What is Cuorips Inc.’s EPS estimate?

Cuorips Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cuorips Inc. have?

Cuorips Inc. has 8,265,366 shares outstanding.

What happened to Cuorips Inc.’s price movement after its last earnings report?

Cuorips Inc. reported an EPS of -¥30.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.324%.

Which hedge fund is a major shareholder of Cuorips Inc.?

Currently, no hedge funds are holding shares in JP:4894

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cuorips Inc.

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.